期刊文献+
共找到3,033篇文章
< 1 2 152 >
每页显示 20 50 100
Nab-paclitaxel(abraxane)-based chemotherapy to treat elderly patients with advanced non-small-cell lung cancer:a single center,randomized and open-label clinical trial 被引量:12
1
作者 Hanrui Chen Xuewu Huang +4 位作者 Shutang Wang Xinting Zheng Jietao Lin Peng Li Lizhu Lin 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2015年第2期190-196,共7页
Background: The purpose of this study is to evaluate the clinical efficacy and safety of abraxane-based chemotherapy with/without nedaplatin in elderly patients with non-small-cell lung cancer (NSCLC). Materials an... Background: The purpose of this study is to evaluate the clinical efficacy and safety of abraxane-based chemotherapy with/without nedaplatin in elderly patients with non-small-cell lung cancer (NSCLC). Materials and methods: From October 2009 to January 2013, 48 elderly patients (≥65 years) with NSCLC were investigated in this clinical trial. The patients were randomized and equally allocated into arms A and AP- (A) abraxane (130 mg/m2, days 1, 8); (B) abraxane + nedaplatin (20 mg/m2 days 1-3, q3w). The parameters of objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and side effects were evaluated between two arms. Results: Over 80% of the patients completed four cycles of chemotherapy. The total ORR was 21.3 %, DCR was 55.3%, PFS 4.5 months and OS 12.6 months. No significant difference was found between arms A and AP in terms of ORR (16.7% vs. 26.1%, P=0.665) or DCR (55.3% vs. 56.5%, P=0.871). The median PFS in arm A was 3.3 months [25-75% confidence interval (CI): 3.1-7.2] and 5.5 months (25-75% CI: 3.2-7.0) in arm AP with no statistical significance (P=0.640). The median OS in arm A was 12.6 months (25-75% CI: 5.7-26.2) and 15.1 months (25-75% CI: 6.4-35.3) in arm AP with no statistical significance (P=0.770). The side effects were mainly grade 1-2. The incidence of grade 3-4 toxicities was 29.1% in arm A and 62.5% in arm AP with a statistical significance (P=0.020). Conclusions: Compared with combined therapy, abraxane alone chemotherapy was beneficial for elderly NSCLC patients with better tolerability and less adverse events, whereas did not significantly differ in terms of ORR, DCR, PFS or OS. 展开更多
关键词 NAB-PACLITAXEL advanced non-small-cell lung cancer (NSCLC) elderly pretreated efficacy
下载PDF
Complete pathological response in locally advanced non-small-cell lung cancer patient: A case report
2
作者 Elisabetta Parisi Donatella Arpa +5 位作者 Giuglia Ghigi Simona Micheletti Elisa Neri Luca Tontini Martina Pieri Antonino Romeo 《World Journal of Clinical Cases》 SCIE 2021年第20期5540-5546,共7页
BACKGROUND Chemotherapy and radiotherapy followed by durvalumab is currently the standard treatment for locally advanced node-positive non-small-cell lung cancer(NSCLC).We describe the case of a patient with locally a... BACKGROUND Chemotherapy and radiotherapy followed by durvalumab is currently the standard treatment for locally advanced node-positive non-small-cell lung cancer(NSCLC).We describe the case of a patient with locally advanced node-positive NSCLC(LA-NSCLC)treated in a phase II prospective protocol with chemotherapy,accelerated hypofractionated radiotherapy(AHRT)and surgery in the preimmunotherapy era.CASE SUMMARY A 69-year-old male,ex-smoker(20 PY),with a Karnofsky performance status of 90,was diagnosed with locally advanced squamous cell lung carcinoma.He was staged by total body computed tomography(CT)scanning,and integrated 18Ffluorodeoxyglucose positron emission tomography/CT scan[cT4 cN3 cM0,stage IIIC according to TNM(tumor-node-metastasis)8th edition]and received AHRT between chemotherapy cycles,in accordance with the study protocol(EudractCT registration 2008-006525-14).At the end of the study the patient underwent surgery,which was not part of the protocol,and showed a complete pathological response.CONCLUSION This case report confirms that AHRT can be used successfully to treat primary LA-NSCLC with bilateral mediastinal lymph node involvement.Our case is of particular interest because of the pathological response after AHRT and the lack of surgical complications.We hypothesize that this radiotherapeutic approach,with its proven efficacy,could be delivered as a short course reducing treatment costs,increasing patient compliance and reducing toxicity.We are currently investigating the possibility of combining hypofractionation,chemotherapy and immunotherapy for patients with LA-NSCLC. 展开更多
关键词 Locally advanced non-small-cell lung cancer Hypofractionated radiotherapy CHEMORADIOTHERAPY Complete pathological response IMMUNOTHERAPY Case report
下载PDF
Clinical observation of docetaxel plus cisplatin versus gemcitabine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer
3
作者 Yongguang Cai Ming Li Xin Xie 《The Chinese-German Journal of Clinical Oncology》 CAS 2011年第8期472-475,共4页
Objective: The aim of this study was to evaluate the clinical efficacy and side effects of docetaxel/cisplatin regiment and gemcitabine/cisplatin regiment in the patients with advanced non-small-cell lung cancer (NS... Objective: The aim of this study was to evaluate the clinical efficacy and side effects of docetaxel/cisplatin regiment and gemcitabine/cisplatin regiment in the patients with advanced non-small-cell lung cancer (NSCLC). Methods: Seventy-six patients with advanced NSCLC who were chemotherapy-naive were enrolled in two groups. In docetaxel group (DP group) the patients received docataxel 75 mg/m^2 and cisplatin 60 mg/m^2 on day 1. In gemcitabine group (GP group) the patients received gemcitabine 1000 mg/m^2 on day 1 and day 8. The dosage of cisplatin was the same as DP group. The two regiments were administrated intravenously every 21 days as a cycle, each patient received 2-4 cycles. All patients were followed up until disease progressed or patients died. Results: The overall response rates were 43.5% in DP group and 45.9% in GP group. The response rate was significantly different between the initial treated group and retreated group in both two groups (53.8% vs 23.0% in DP group and 56% vs 25% in GP group, P 〈 0.05, respectively). The main side effects were bone marrow suppression and thrombocytopenia. Conclusion: Docetaxel/cisplatin regiment and gemcitabine/cisplatin regiment for the patients with advanced NSCLC were efficient and well-tolerated chemotherapeutic approachs with low toxicity levels. The efficacy and major toxicity in two groups were similar. 展开更多
关键词 docetaxel/cisplatin gemcitabine/cisplatin advanced non-small-cell lung cancer (NSCLC)
下载PDF
Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer:A phase II open-label clinical study 被引量:9
4
作者 Shanshan Qin Hui Yu +10 位作者 Xianghua Wu Zhiguo Luo Huijie Wang Si Sun Mingzhu Huang Jia Jin Zhonghua Tao Jie Qiao Yu Feng Jialei Wang Jianhua Chang 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2019年第2期339-348,共10页
Objective: The aim of this trial was to compare both the efficacy and the safety of a weekly nanoparticle albumin-bound paclitaxel(nab-paclitaxel) plus cisplatin vs. gemcitabine plus cisplatin in patients with advance... Objective: The aim of this trial was to compare both the efficacy and the safety of a weekly nanoparticle albumin-bound paclitaxel(nab-paclitaxel) plus cisplatin vs. gemcitabine plus cisplatin in patients with advanced non-small-cell lung cancer(NSCLC).Methods: A total of 84 participants received either 100 mg/m^2 nab-paclitaxel each week on d 1, 8 and 15 of a 28 day cycle, as well as cisplatin 75 mg/m^2 on d 1 every three weeks(nab-TP arm); or gemcitabine 1,000 mg/m^2 on d 1 and 8, plus cisplatin 75 mg/m^2 on d 1 every three weeks(GP arm). The primary end point was progression-free survival(PFS). The secondary end points were overall response rate(ORR) and overall survival(OS).Results: According to our analysis, the median PFS was 4.8 months for the nab-TP arm vs. 5.2 months for the GP arm(P=0.55). Analysis showed the median OS was 14.6 months for participants who were in the nab-TP arm vs. 15.1 months for those in the GP arm(P=0.94). Besides, nab-TP showed OS advantages over GP in patients harboring epidermal growth factor receptor(EGFR) mutation(26.7 vs. 15.3 months, P=0.046) and patients with a performance status of 0(23.5 vs. 14.7 months, P=0.020). It was found that incidences of drug-related grade 3 or 4 toxicities were comparable between the two treatment arms.Conclusions: Therefore, it can be seen that weekly nab-TP treatment has a similar efficacy and tolerability to GP treatment for patients who are undergoing their first-line treatment for NSCLC. It could be that survival differences among platinum doublets in the context of both EGFR mutation and performance status have the potential to be the basis for our further clinical trials. 展开更多
关键词 Albumin-bound paclitaxel CISPLATIN GEMCITABINE FIRST-LINE therapy advanced non-small-cell lung cancer
下载PDF
Achievable complete remission of advanced non-small-cell lung cancer: Case report and review of the literature 被引量:5
5
作者 Ning-Ning Yang Fei Xiong +1 位作者 Qing He Yong-Song Guan 《World Journal of Clinical Cases》 SCIE 2018年第7期150-155,共6页
Surgery is the first choice of treatment for patients with non-small-cell lung cancer(NSCLC), but few patients can be treated surgically because of either advanced disease or poor pulmonary function. Other therapies i... Surgery is the first choice of treatment for patients with non-small-cell lung cancer(NSCLC), but few patients can be treated surgically because of either advanced disease or poor pulmonary function. Other therapies include radiotherapy and chemotherapy, as well as complementary and alternative therapies, usually with disappointing results. Bronchial artery infusion(BAI) is a manageable and effective method for treating advanced NSCLC. Outcome is good by BAI due to its repeatability and low toxicity. Icotinib hydrochloride is a newly developed and highly specific epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor and has been safely and efficiently used to treat advanced NSCLC. We herein report a 73-year-old patient with chronic cough, who was diagnosed with advanced NSCLC with the EGFR mutation of L858 R substitution in exon 21, and treated with the combination of oral icotinib and BAI chemotherapy as the first-line therapy, which resulted in a satisfactory clinical outcome. Complete remission of advanced NSCLC can be achieved using the combination of oral icotinib and BAI chemotherapy. 展开更多
关键词 TYROSINE kinase inhibitor BRONCHIAL artery infusion ICOTINIB HYDROCHLORIDE EPIDERMAL growth factor receptor advanced non-small-cell lung cancer
下载PDF
Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small-cell lung cancer 被引量:2
6
作者 Pu-Yuan Xing Jun-Ling Li +5 位作者 Yan Wang Xue-Zhi Hao Bin Wang Lin Yang Yuan-Kai Shi Xiang-Ru Zhang 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2013年第2期200-205,共6页
Objective: To observe the efficacy and safety of albumin-bound paclitaxel (ABP) monotherapy in treating recurrent advanced non-small-cell lung cancer (NSCLC). Methods: We retrospectively analyzed the short-term ... Objective: To observe the efficacy and safety of albumin-bound paclitaxel (ABP) monotherapy in treating recurrent advanced non-small-cell lung cancer (NSCLC). Methods: We retrospectively analyzed the short-term efficacy and toxicities of ABP monotherapy in treating 21 patients who had previously undergone multiple cycles of therapy for their advanced NSCLC in our hospital since 2010. The treatment-related survival was also analyzed. Results: Of these 21 patients, the best overall response was partial response (PR) in 6 patients (28.6%), stable disease (SD) in I0 patients (47.6%), and progressive disease (PD) in 5 patients (23.8%). The overall response rate (ORR) was 28.6% and the disease control rate (DCR) (PR + SD) was 76.2%. The median progression-flee survival (PFS) was 4.0 months (95% CI, 5.0-7.0 months). The main grade 3/4 toxicities included neutropenia (11.1%), peripheral nerve toxicity (5.6%), muscle and joint aches (5.6%), and fatigue (5.6%). Conclusions: The ABP monotherapy can achieve good objective response in advanced NSCLC patients who have previously received multiple cycles of treatment and be well tolerated. 展开更多
关键词 Albumin-bound paclitaxel PACLITAXEL advanced non-small cell lung cancer CHEMOTHERAPY
下载PDF
Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study 被引量:2
7
作者 Puyuan Xing Di Ma +10 位作者 Qiang Wang Xuezhi Hao Mengzhao Wang Yan Wang Li Shan Tao Xin Li Liang Hongge Liang Yang Du Zhaohui Zhang Junling Li 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2019年第3期481-488,共8页
Objective: Crizotinib has demonstrated promising efficacy in patients with anaplastic lymphoma kinase(ALK)-positive non-small-cell lung cancer(NSCLC) in clinical trials. We conducted this retrospective multicenter stu... Objective: Crizotinib has demonstrated promising efficacy in patients with anaplastic lymphoma kinase(ALK)-positive non-small-cell lung cancer(NSCLC) in clinical trials. We conducted this retrospective multicenter study to assess the outcomes of crizotinib therapy in, to our knowledge, a large sample cohort of patients with ALKpositive advanced NSCLC.Methods: We reviewed the medical records of 484 unselected ALK-positive NSCLC patients treated with crizotinib at 5 cancer centers in China from January 2013 to November 2017. Clinical data were collected from the initiation of crizotinib therapy to Response Evaluation Criteria in Solid Tumors(RECIST)-defined progressive disease(PD).Results: A total of 428 eligible ALK-positive NSCLC patients were enrolled, 273(63.8%) of whom received crizotinib as first-line treatment. The median progression-free survival(PFS) and overall survival(OS) from the initiation of crizotinib treatment were 14.4 [95% confidence interval(95% CI), 12.4-16.4] months and 53.4(95%CI, 33.7-73.1) months, respectively. In subgroup analyses, patients who received crizotinib as first-line treatment showed a higher disease control rate(DCR) and a longer median OS compared with second-/later-line crizotinib treatment(94.8% and OS not reached vs. 89.0% and 40.5 months, respectively). For 261 patients with RECISTdefined PD, multivariate Cox analysis revealed that in patients who received first-line crizotinib therapy, continued crizotinib beyond progressive disease(CBPD) and next-generation ALK inhibitors after crizotinib failure were associated with improved survival.Conclusions: This study has demonstrated the clinically meaningful benefit of crizotinib treatment in a large cohort of Chinese ALK-positive NSCLC patients. CBPD and next-generation ALK inhibitor treatment may provide improved survival after RECIST-defined progression on crizotinib. 展开更多
关键词 CRIZOTINIB ANAPLASTIC LYMPHOMA KINASE non-small-cell lung cancer real-world study
下载PDF
A phase I study of nimotuzumab plus docetaxel in chemotherapy- refractory/resistant patients with advanced non-small-cell lung cancer 被引量:3
8
作者 Jun Zhao Minglei Zhuo +6 位作者 Zhijie Wang Jianchun Duan Yuyan Wang Shuhang Wang Tongtong An Meina Wu Jie Wang 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2016年第1期12-18,共7页
Background: To determine the safety and therapeutic efficacy of nimotuzumab (h-R3) combined with docetaxel in advanced non-small-cell lung cancer (NSCLC) patients who have failed to respond to prior first-line ch... Background: To determine the safety and therapeutic efficacy of nimotuzumab (h-R3) combined with docetaxel in advanced non-small-cell lung cancer (NSCLC) patients who have failed to respond to prior first-line chemotherapy. Methods: In this single-center, open-label, dose-escalating phase I trial, patients with epidermal growth factor receptor (EGFR)-expressing stage IV NSCLC were treated with nimotuzumab plus doeetaxel according to a dose escalation schedule. The safety and efficacy of the combination treatment were observed and analyzed.Results: There were 12 patients with EGFR-expressing stage IV NSCLC enrolled. The dose of nimotuzumab was escalated from 200 to 600 mg/week. The longest administration of study drug was 40 weeks at the 600 mg/week dose level. Grade Ⅲ-Ⅳ toxicities included neutropenia and fatigue, and other toxicities included rash. Dose-limiting toxicity occurred with Grade 3 fatigue at the 200 mg dose level of nimotuzumab and Grade 4 neutropenia with pneumonia at the 600 mg dose level of nimotuzumab. No objective responses were observed, and stable disease was observed in eight patients (66.7%). The median progression-free survival (PFS) was 4.4 months in all patients, 1.3 months in patients with the EGFR mutation, and 4.4 months in those with wild type EGFR (EGFR WT). The median survival time (MST) was 21.1 months in all patients, 21.1 months in patients with EGFR mutation, and 26.4 months in patients with EGFR WT. Conclusions: Nimotuzumab and docetaxel combination therapy was found to be well tolerated and efficacious. Further study of nimotuzumab is warranted in advanced NSCLC patients. 展开更多
关键词 NIMOTUZUMAB DOCETAXEL non-small-cell lung cancer (NSCLC)
下载PDF
Clinical observation of pemetrexed on advanced non-small-cell lung cancer 被引量:4
9
作者 Yongfa Zheng Wei Ge Ling Zhang Zhenyu Zhao Fangfang Jie 《The Chinese-German Journal of Clinical Oncology》 CAS 2011年第3期140-143,共4页
Objective: The aim of our study was to observe the efficacy and toxicity of 50 cases of advanced non-small cell lung cancer (NSCLC) patients treated by pemetrexed. Methods: Fifty patients, including 29 females and... Objective: The aim of our study was to observe the efficacy and toxicity of 50 cases of advanced non-small cell lung cancer (NSCLC) patients treated by pemetrexed. Methods: Fifty patients, including 29 females and 21 males, with a median age 62 years (35–82 years), 13 of whom were treated with pemetrexed only and the left 37 cases were treated with pemetrexed combined with platinum in the Department of Oncology, Renmin Hospital of Wuhan University from June 2006 to March 2009. Single agent regimen: patients received pemetrexed 500 mg/m2 on day 1 with every 21 days. Combination regimen: patients received pemetrexed 500 mg/m2 on day 1 and carboplatin 300 mg/m2 on day 1 or cisplatin 35 mg/m2 on day 1 to day 3 or nedaplatin 80 mg/m2 on day 1 by intravenous infusion with 21 days as one cycle. RECIST 1.0 standard was used to evaluate the clinical efficiency, and the WHO toxicity standard was used to evaluate toxic reaction, and the QOL was used to evaluate the quality of life. Results: All patients were given 162 cycles (at least 2 cycles, at most 6 cycles) and the response rate of all the patients were evaluated. There were 2 complete remission (CR), 7 partial remission (PR), 22 stable disease (SD) and 19 progressive disease (PD) in the group, the overall response rate was (RR) was 18.0% and disease control rate (DCR) 62.0%. The quality of life improvement rate reaches 58.0%. The major toxic reaction included neutropenia, thrombocytopenia, hypemia, nausea, and vomiting. Most of the severity of these effects was grade I–II and well tolerated. Conclusion: Chemotherapy with pemetrexed or pemetrexed combined with platinum in the treatment of advanced non-small cell lung cancer is effective, safe and well-tolerable, which can improve quality of life of the patient. 展开更多
关键词 non-small-cell lung cancer PEMETREXED CHEMOTHERAPY
下载PDF
Immediate Versus Delayed Treatment with EGFR Tyrosine Kinase Inhibitors after First-line Therapy in Advanced Non-small-cell Lung Cancer 被引量:1
10
作者 Zhi-jie Wang Tong-tong An +10 位作者 Tony Mok Lu Yang Hua Bai Jun Zhao Jian-chun Duan Mei-na Wu Yu-yan Wang Ping-ping Li Hong Sun Ping Yang Jie Wang 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2011年第2期112-117,共6页
Objective: To analyze the outcomes of patients who received TKI immediately after the first-line without progression as maintenance treatment (immediate group) vs. those received delayed treatment upon disease prog... Objective: To analyze the outcomes of patients who received TKI immediately after the first-line without progression as maintenance treatment (immediate group) vs. those received delayed treatment upon disease progression as second-line therapy (delayed group). Methods: The study included 159 no-small-cell lung cancer (NSCLC) patients who received gefitinib or erlotinib as maintenance treatment in the immediate group (85 patients) or as second-line therapy in the delayed group (74 patients). The primary end point was progression-free survival (PFS). EGFR mutation status was detected using denaturing high-performance liquid chromatography (DHPLC). Results: PFS was 17.3 and 16.4 months in the immediate and delayed groups, respectively (hazard ratio [HR], 0.99; 95% Confidence Interval [CI]: 0.69-1.42; P=0.947). In a subgroup analysis that included only patients with EGFR mutation, however, PFS was significantly longer in the immediate group than in the delayed group (HR, 0.48; 95% CI: 0.27-0.85; P=0.012). In patients with wild type EGFR, the risk for disease progression was comparable between the two groups (HR, 1.23; 95% CI: 0.61-2.51; P=0.564). No significant difference was demonstrated between the immediate and delayed group in terms of the overall survival (OS) (26.1 months vs. 21.6 months, respectively; HR=0.53; 95% CI: 0.27 to 1.06; P=0.072). There was also no difference in the incidence of adverse events between the two groups. Conclusions: EGFR TKI maintenance improves PFS in patients with EGFR mutation. Prospectively designed clinical studies that compare TKI immediate vs. delayed treatment after first-line chemotherapy upon disease progression are needed. 展开更多
关键词 EGFR tyrosine kinase inhibitor Maintenance therapy non-small-cell lung cancer
下载PDF
Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation:A case report
11
作者 Fei Xu Meng-Ling Xia +2 位作者 Hui-Yun Pan Jiong-Wei Pan Yi-Hong Shen 《World Journal of Clinical Cases》 SCIE 2022年第17期5916-5922,共7页
BACKGROUND Tyrosine kinase inhibitors(TKI)have been the standard first-line therapy for advanced non-small cell lung cancer(NSCLC)of epidermal growth factor receptor(EGFR)sensitive mutations.Uncommon EGFR mutations ar... BACKGROUND Tyrosine kinase inhibitors(TKI)have been the standard first-line therapy for advanced non-small cell lung cancer(NSCLC)of epidermal growth factor receptor(EGFR)sensitive mutations.Uncommon EGFR mutations are increasingly reported with the development of next-generation sequencing.However,their sensitivity to TKIs is variable with limited clinical evidence.CASE SUMMARY Here,we report a patient with the rare delE709_T710insD mutation,who showed the favorable efficacy of dacomitinib and achieved a partial response with a progression-free survival of 7.0 mo.CONCLUSION To our knowledge,this is the first report displaying the clinical efficacy of dacomitinib for patients with delE709_T710insD,which may help to provide alternatives in non-classical variant NSCLC patients.Further studies are warranted to make the optimal choice of EGFR-TKI for rare mutations. 展开更多
关键词 Next-generation sequencing DelE709_T710insD non-small-cell lung cancer Dacomitinib Uncommon EGFR mutation Case report
下载PDF
The short-term efficacy of icotinib on the treatment of advanced non-small-cell lung cancer
12
作者 Jianing Jiang Cong Liu +6 位作者 Kun Deng Jinbo Zhao Man Li Jinghua Sun Li Li Liying Ban Xiuhua Sun 《The Chinese-German Journal of Clinical Oncology》 CAS 2014年第1期1-5,共5页
Objective: The aim of the study was, (1) to observe the short-term efficacy and adverse reactions of icotinib hydrochloride on the treatment of advanced non-small cell lung cancer (NSCLC); (2) to explore whethe... Objective: The aim of the study was, (1) to observe the short-term efficacy and adverse reactions of icotinib hydrochloride on the treatment of advanced non-small cell lung cancer (NSCLC); (2) to explore whether there is difference in the efficacy of icotinib hydrochloride among the subgroups of sex, age, smoking history, classification of CEA, histological type, multi-line treatment and PS score. Methods: The study was conducted to collect 138 patients taking icotinib hydrochloride with advanced non-small cell lung cancer in hospitals of Dalian (China) from September 1st 2011 to June 14th 2012. All patients had taken icotinib hydrochloride (125 mg three times a day) until the disease was progressed or the adverse reactions could not be tolerated. During the period of taking it, other anti-tumor treatments were forbidden. We observed the symptoms, such as cough, short breath, hemoptysis, pain. The objective efficacy was evaluated by RECIST criteria, and the adverse reactions related to the treatment was assessed on the basis of NCl-CTC 3.0. Results: Of all patients, CR was 1 (0.7%), PR was 59 (42.8%), SD was 37 (26.8%), PD was 41 (29.7%). And ORR was 43.5% (60/138), DCR 70.3% (97/138). The DCR of females was 83.5% (71/85) versus 49.1% (26/53) of males. The difference of ORR and DCR between the two subgroups had statistical significance (X2 = 8.065, P = 0.05; X2 = 18.577, P = 0.000). The difference of ORR and DCR between the subgroups of patients after or before 70 years old had no statistical significance. The difference of ORR and DCR between the subgroups of smoking and non-smoking had statistical significance (X2 = 8.492; X2 = 13.602). The difference of ORR and DCR between the CEA subgroups had statistical significance (X2 = 14.141; X2 = 14.160), showed 81 patients with abnormal CEA before the treatment with ORR 56.8.0% (46/81), DCR 81.5% (66/81); 57 patients of normal CEA before the treatment with ORR 24.6% (14/57), DCR 52.6% (30/57). The 36 patients (26.1%) using icotinib hydrochloride as the first-line treatment, 78 patients (56.5%) using icotinib hydrochloride as the second-line, 20 patients (14.5%) using icotinib hydrochloride as the third-line, and 4 patients (2.9%) with tyrosine kinase inhibitor (TKI) resistance, there was statistical difference of DCR among the multi-groups above (~2 = 11.734, P = 0.008). ORR was 31.1% (14/45) versus DCR 53.3% (24/45) in 45 patients with PS 3-4 points, and ORR was 49.4% (46/93) versus DCR 78.5% (73/93) in 93 patients with PS 0-2 points, and there was statistical difference (X2 = 4.156; X2 = 9.149). The main adverse reactions were rash (26.8%), diarrhea (13.8%), mild liver function abnormal (10.9%). Conclusion: The short-term efficacy of icotinib hydrochloride on the treatment of advanced NSCLC is positive, and the relevant adverse reactions are mild. The efficacy is better when the patient is female, non-smoker, treated as first-line, with higher CEA before treatment and lower PS scores. 展开更多
关键词 non-small-cell lung cancer (NSCLC) icotinib hydrochloride EFFICACY
下载PDF
Therapeutic Effects of Kanglaite Injection Combined with Chemotherapy on Advanced Non-small-cell Lung Cancer
13
作者 Zhaoji Luan 《Proceedings of Anticancer Research》 2018年第4期1-4,共4页
The objective of this study was to study the therapeutic effect of Kanglaite injection combined with chemotherapy in the treatment of late-stage nonsmall-cell lung cancer(NSCLC)and also to observe the effect of the co... The objective of this study was to study the therapeutic effect of Kanglaite injection combined with chemotherapy in the treatment of late-stage nonsmall-cell lung cancer(NSCLC)and also to observe the effect of the combination treatment on immune function.92 patients with advanced stage of NSCLC who admitted to First Hospital of Zibo city hospital from May 2017 to October 2018 were randomly divided into experimentagroup and control group,with 46 cases,respectively.The control group was treated with chemotherapy only while the experimental group was treated with Kanglaite injection combined with chemotherapy which was the basic treatment for patients,and the total treatment effective rate,adverse reaction rate,and immune index of the treatments on two groups were compared.The total treatment effective rate of the experimental group was 80.43%,which was significantly higher than that of the control group,which was 63.04%.The incidence of adverse reactions in the experimental group was 36.96%,which was lower than that of the control group(78.26%).The immune indexes of the experimental group(CD3+,CD4+,IgG,and IgA)were better than that of the control group,respectively.The differences between the two groups were statistically significant(P<0.05).During the chemotherapy of late-stage or advanced NSCLC,the addition use of Kanglaite injection has a significant effect on improving tumor control and reducing the side effects of chemotherapy,and helps to improve the immune function of patients;thus,it is worth promoting. 展开更多
关键词 KANGLAITE injection CHEMOTHERAPY advanced non-small-cell lung cancer ADVERSE reactions IMMUNE function
下载PDF
Genomic correlates of the response to first-line PD-1 blockade plus chemotherapy in patients with advanced non-small-cell lung cancer
14
作者 Tao Jiang Jian Chen +11 位作者 Haowei Wang Fengying Wu Xiaoxia Chen Chunxia Su Haiping Zhang Fei Zhou Ying Yang Jiao Zhang Huaibo Sun Henghui Zhang Caicun Zhou Shengxiang Ren 《Chinese Medical Journal》 SCIE CAS CSCD 2024年第18期2213-2222,共10页
Background:Programmed death 1(PD-1)blockade plus chemotherapy has become the new first-line standard of care for patients with advanced non-small-cell lung cancer(NSCLC).Yet not all NSCLC patients benefit from this re... Background:Programmed death 1(PD-1)blockade plus chemotherapy has become the new first-line standard of care for patients with advanced non-small-cell lung cancer(NSCLC).Yet not all NSCLC patients benefit from this regimen.This study aimed to investigate the predictors of PD-1 blockade plus chemotherapy in untreated advanced NSCLC.Methods:We integrated clinical,genomic,and survival data from 287 patients with untreated advanced NSCLC who were enrolled in one of five registered phase 3 trials and received PD-1 blockade plus chemotherapy or chemotherapy alone.We randomly assigned these patients into a discovery cohort(n=125),a validation cohort(n=82),and a control cohort(n=80).The candidate genes that could predict the response to PD-1 blockade plus chemotherapy were identified using data from the discovery cohort and their predictive values were then evaluated in the three cohorts.Immune deconvolution was conducted using transcriptome data of 1014 NSCLC patients from The Cancer Genome Atlas dataset.Results:A genomic variation signature,in which one or more of the 15 candidate genes were altered,was correlated with significantly inferior response rates and survival outcomes in patients treated with first-line PD-1 blockade plus chemotherapy in both discovery and validation cohorts.Its predictive value held in multivariate analyses when adjusted for baseline parameters,programmed cell death ligand 1(PD-L1)expression level,and tumor mutation burden.Moreover,applying both the 15-gene panel and PD-L1 expression level produced better performance than either alone in predicting benefit from this treatment combination.Immune landscape analyses revealed that tumors with one or more variation in the 15-gene panel were associated with few immune infiltrates,indicating an immune-desert tumor microenvironment.Conclusion:These findings indicate that a 15-gene panel can serve as a negative prediction biomarker for first-line PD-1 blockade plus chemotherapy in patients with advanced NSCLC. 展开更多
关键词 non-small-cell lung cancer(NSCLC) Programmed death 1(PD-1)blockade Gene panel Prediction BIOMARKER
原文传递
Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors 被引量:1
15
作者 Nijiao Li Xuliang Zheng +5 位作者 Jinyan Gan Ting Zhuo Xiaohong Li Chuyi Yang Yanbin Wu Shouming Qin 《Chinese Medical Journal》 SCIE CAS CSCD 2023年第21期2562-2572,共11页
Background:Lung cancer is the second most common cancer worldwide,with non-small-cell lung cancer(NSCLC)accounting for the majority of cases.Patients with NSCLC have achieved great survival benefits from immunotherapi... Background:Lung cancer is the second most common cancer worldwide,with non-small-cell lung cancer(NSCLC)accounting for the majority of cases.Patients with NSCLC have achieved great survival benefits from immunotherapies targeting immune checkpoints.Glucocorticoids(GCs)are frequently used for palliation of cancer-associated symptoms,as supportive care for noncancer-associated symptoms,and for management of immune-related adverse events(irAEs).The aim of this study was to clarify the safety and prognostic significance of glucocorticoid use in advanced patients with NSCLC treated with immune checkpoint inhibitors(ICIs).Methods:The study searched publications from PubMed,Embase,Cochrane Library,Web of Science,China Biology Medicine disc,Chinese National Knowledge Infrastructure,Wanfang Data,and Chinese Science and Technology Journal Database up to March 1st,2022,and conducted a meta-analysis to assess the effects of glucocorticoid use on overall survival(OS)and progressionfree survival(PFS)in NSCLC patients treated with ICIs through the available data.The study calculated the pooled hazard ratios(HRs)and 95%confidence intervals(CIs).Results:This study included data from 25 literatures that were mainly retrospective,with 8713 patients included.Patients taking GCs had a higher risk for tumor progression and death compared with those not taking GCs(PFS:HR=1.57,95%CI:1.33-1.86,P<0.001;OS:HR=1.63,95%CI:1.41-1.88,P<0.001).GCs used for cancer-associated symptoms caused an obviously negative effect on both PFS and OS(PFS:HR=1.74,95%CI:1.32-2.29,P<0.001;OS:HR=1.76,95%CI:1.52-2.04,P<0.001).However,GCs used for irAEs management did not negatively affect prognosis(PFS:HR=0.68,95%CI:0.46-1.00,P=0.050;OS:HR=0.53,95%CI:0.34-0.83,P=0.005),and GCs used for non-cancer-associated indications had no effect on prognosis(PFS:HR=0.92,95%CI:0.63-1.32,P=0.640;OS:HR=0.91,95%CI:0.59-1.41,P=0.680).Conclusions:In advanced NSCLC patients treated with ICIs,the use of GCs for palliation of cancer-associated symptoms may result in a worse PFS and OS,indicating that they increase the risk of tumor progression and death.But,in NSCLC patients treated with ICIs,the use of GCs for the management of irAEs may be safe,and the use of GCs for the treatment of non-cancer-associated symptoms may not affect the ICIs’survival benefits.Therefore,it is necessary to be careful and evaluate indications rationally before administering GCs in individualized clinical management. 展开更多
关键词 GLUCOCORTICOIDS Immune checkpoint inhibitor Meta-analysis non-small-cell lung cancer Prognosis
原文传递
Returning from the afterlife?Sotorasib treatment for advanced KRAS mutant lung cancer:A case report
16
作者 Ming-Xing Wang Pei Zhu +2 位作者 Yue Shi Qing-Ming Sun Wan-Hui Dong 《World Journal of Clinical Cases》 SCIE 2024年第25期5805-5813,共9页
BACKGROUND Lung cancer is increasing in incidence worldwide,and targeted therapies are developing at a rapid pace.Furthermore,the KRAS specific gene is strongly associated with non-small cell lung cancer(NSCLC).Adult ... BACKGROUND Lung cancer is increasing in incidence worldwide,and targeted therapies are developing at a rapid pace.Furthermore,the KRAS specific gene is strongly associated with non-small cell lung cancer(NSCLC).Adult patients with locally advanced or metastatic NSCLC who have tested positive for the KRAS G12C mutation and have progressed after at least one systemic treatment are treated with sotorasib.CASE SUMMARY In this study,we report on an advanced NSCLC with a KRAS G12C mutation.The histological diagnosis indicates stage IVB left lung adenocarcinoma with pelvic and bone metastases,identified as cT4N2bM1c.Using circulating tumor DNA analysis,it was possible to determine the mutation abundance of the KRAS gene exon 2,c.34G>Tp.G12C,which was 32.3%.The patient was advised to take sotorasib as part of their treatment.The imaging data were compared before and after treatment.Furthermore,clinical reassessments and regular serial blood testing were conducted.We found that the patient’s clinical symptoms significantly improved after receiving sotorasib medication,and there were no notable side effects,such as liver toxicity,during the treatment.CONCLUSION Sotorasib has shown promising clinical efficacy in patients with the KRAS G12c mutation and has no apparent toxic side effects. 展开更多
关键词 Non-small cell lung cancer Sotorasib KRAS G12C Targeted therapy advanced carcinoma Case report
下载PDF
Pang Fuwan Uses Yao Medicine to Observe the Therapeutic Effects on the Physical and Mental Symptoms of Patients with Advanced Non-Small Cell Lung Cancer
17
作者 Qiuxiang Luo Qiongping Liang Xiaoyan Luo 《Pharmacology & Pharmacy》 2024年第3期62-69,共8页
Objective: Investigate the efficacy and safety of Yao Medicine in the treatment of advanced non-small-cell lung carcinoma, and explore the best therapeutic measure for clinical benefit. Methods: From July 2020 to July... Objective: Investigate the efficacy and safety of Yao Medicine in the treatment of advanced non-small-cell lung carcinoma, and explore the best therapeutic measure for clinical benefit. Methods: From July 2020 to July 2022, 84 patients with advanced non-small-cell lung carcinoma were selected and randomly divided into the Observation Group and control group, and the control group was treated with routine Western medicine, with 42 cases in each group. The activity of daily living (ADL) was assessed before and after treatment, meanwhile, the self-rating depression scale (SDS) and self-rating anxiety SAS (SAS) were used to assess the improvement of a bad mood, and quality of life SF-36 was used to assess the quality of life, to judge the efficacy and safety. Results: The effective rate of observation group was 91.67%. The effective rate of the control group was 76.19%. The effective rate of the observation group was significantly higher than that of the control group (P 0.05). There were no significant differences in the scores of SDS, SAS and quality of life between the two groups before treatment (P > 0.05), and after treatment, the scores of SDS, SAS and quality of life in the two groups were compared with those in the control group (P > 0.05), the scores of VAS, SDS and SAS decreased significantly, while ESCV, angle of straight leg elevation, ADL, physiological score, emotional score, social score and health status score increased significantly, the difference was statistically significant (P 0.05). Conclusion: Yao Medicine can improve the psychosomatic symptoms of patients with advanced non-small-cell lung carcinoma better, with better efficacy and higher safety. 展开更多
关键词 Yao Medicine non-small-cell lung Carcinoma advanced Stage EFFICACY Physical and Mental
下载PDF
Analysis of the Status Quo and Influencing Factors of Advanced Lung Cancer Patients’ Quality of Life
18
作者 Xuehong Tang Tao Tang Xuemei Jiang 《Journal of Clinical and Nursing Research》 2024年第10期113-119,共7页
Objective:To investigate the quality of life and related influencing factors of patients with advanced lung cancer.Methods:A cross-sectional survey was conducted on 51 patients with advanced lung cancer who were hospi... Objective:To investigate the quality of life and related influencing factors of patients with advanced lung cancer.Methods:A cross-sectional survey was conducted on 51 patients with advanced lung cancer who were hospitalized in the Department of Oncology from January 2023 to December 2023,and the influencing factors of patients’quality of life were analyzed.Results:Among the five functional scales(physical,role,cognitive,emotional,and social functioning)of the QLQ-C30 scale,the social and emotional function scores were the lowest,respectively 16.7(IQR:0,33.3)points,and 16.7(IQR:8.3,25),and among the three symptom scales(fatigue,pain,nausea and vomiting),the fatigue symptom score was the highest:77.7(IQR:66.7,88.9)points.The results of Spearman correlation analysis showed that the anxiety score of patients with advanced lung cancer was positively correlated with depression score(P<0.01),while the quality of life of patients with advanced lung cancer was not correlated with anxiety and depression score(P>0.1).The self-care ability,the nature of the disease,and whether the patient was treated for chemotherapy were the independent influencing factors of the patient’s quality of life,and the difference was statistically significant(P<0.001).Conclusion:Patients with advanced lung cancer have different degrees of anxiety and depression,and their quality of life is affected by many factors,which are mainly related to the patient’s self-care ability,the nature of the disease,and whether they received chemotherapy. 展开更多
关键词 advanced lung cancer Quality of life ANXIETY DEPRESSION
下载PDF
Analysis of the Efficacy,Progression-Free Survival,and Safety of Anlotinib in Advanced Lung Cancer Treatment
19
作者 Jie Shen Cheng Meng +2 位作者 Xiaoyan Zhang Rong Lei Liyun Hao 《Proceedings of Anticancer Research》 2024年第1期105-111,共7页
Objective:To analyze the clinical efficacy,progression-free survival,and safety of anlotinib in the treatment of advanced lung cancer.Methods:A retrospective analysis was conducted using data from 60 patients with adv... Objective:To analyze the clinical efficacy,progression-free survival,and safety of anlotinib in the treatment of advanced lung cancer.Methods:A retrospective analysis was conducted using data from 60 patients with advanced lung cancer treated with anlotinib from May 2019 to May 2021.This analysis aimed to comprehensively evaluate the clinical efficacy,progression-free survival,and adverse reactions of anlotinib.Results:The median progression-free survival(PFS)for the 60 patients was 5.79 months,with an overall response rate(ORR)of 21%and a disease control rate(DCR)of 90%.In the first-line group,the median PFS was 6.20 months,ORR was 76.92%,and DCR was 84.61%.The second-line group showed a median PFS of 6.30 months,ORR of 28.57%,and DCR of 90.48%.In the third-line group,the median PFS was 5.34 months,ORR was 19.23%,and DCR was 92.30%.The single-agent group exhibited a median PFS of 5.09 months,ORR of 23.33%,and DCR of 76.67%.In the combination group,the median PFS was 6.53 months,ORR was 46.67%,and DCR was 100%.The combination group demonstrated a significantly higher medication effect than the single-drug group,and adverse drug reactions were mostly grade 1-2.Conclusion:Anlotinib exhibits a better disease control rate and survival benefit in the treatment of advanced lung cancer.The combination effect is superior to monotherapy,with relatively controllable adverse effects. 展开更多
关键词 Anlotinib advanced lung cancer Vascular targeted therapy Recent efficacy Drug safety
下载PDF
Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer,one year follow-up 被引量:21
20
作者 Yong-song GUAN Yuan LIU +4 位作者 Qing ZOU Qing HE Zi LA Lin YANG Ying HU 《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》 SCIE CAS CSCD 2009年第5期331-340,共10页
Objective: In the present study, we have examined the safety and efficacy of recombinant adenovirus encoding human p53 tumor suppressor gene (rAd-p53) injection in patients with advanced non-small-cell lung cancer ... Objective: In the present study, we have examined the safety and efficacy of recombinant adenovirus encoding human p53 tumor suppressor gene (rAd-p53) injection in patients with advanced non-small-cell lung cancer (NSCLC) in the combination with the therapy of bronchial arterial infusion (BAI). Methods: A total of 58 patients with advanced NSCLC were enrolled in a non-randomized, two-armed clinical trial. Of which, 19 received a combination treatment of BAI and rAd-p53 (the combo group), while the remaining 39 were treated with only BAI (the control group). Patients were followed up for 12 months, with safety and local response evaluated by the National Cancer lnstitute's Common Toxicity Criteria and response evaluation criteria in solid tumor (RECIST), respectively. Time to progression (TTP) and survival rates were also analyzed by Kaplan-Meier method. Results In the combo group, 19 patients received a total of 49 injections ofrAd-p53 and 46 times of BAI, respectively, while 39 patients in the control group received a total of 113 times of BAI. The combination treatment was found to have less adverse events such as anorexia, nausea and emesis, pain, and leucopenia (P〈0.05) but more arthralgia, fever, influenza-like symptom, and myalgia (P〈0.05), compared with the control group. The overall response rates (complete response (CR)+partial response (PR)) were 47.3% and 38.4% for the combo group and the control group, respectively (P〉0.05). Patients in the combo group had a longer TTP than those in the control group (a median 7.75 vs 5.5 months, P-0.018). However, the combination treatment did not lead to better survival, with survival rates at 3, 6, and 12 months in the combo group being 94.74%, 89.47%, and 52.63%, respectively, com- pared with 92.31%, 69.23%, and 38.83% in the control group (P=0.224). Conclusion: Our results show that the combination of rAd-p53 and BAI was well tolerated in patients with NSCLC and may have improved the quality of life and delayed the disease progression. A further study to better determine the efficacy of this combination therapy is warranted. 展开更多
关键词 RAd-p53 gene therapy Clinical trial non-small-cell lung cancer (NSCLC) Bronchial arterial infusion (BAI)
原文传递
上一页 1 2 152 下一页 到第
使用帮助 返回顶部